Apollo Commercial Real Estate Finance Inc
F:9A1
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Apollo Commercial Real Estate Finance Inc
F:9A1
|
US |
|
Aspen Pharmacare Holdings Ltd
F:LDZA
|
ZA |
|
P
|
PDS Biotechnology Corp
F:EU6
|
US |
|
Logitech International SA
SIX:LOGN
|
CH |
|
P
|
Ping An Insurance Group Co of China Ltd
F:PZX
|
CN |
Wall St Price Targets
9A1 Price Targets Summary
Apollo Commercial Real Estate Finance Inc
According to Wall Street analysts, the average 1-year price target for 9A1 is 9.7 EUR with a low forecast of 9.19 EUR and a high forecast of 10.42 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is 9A1's stock price target?
Price Target
9.7
EUR
According to Wall Street analysts, the average 1-year price target for 9A1 is 9.7 EUR with a low forecast of 9.19 EUR and a high forecast of 10.42 EUR.
What is the Revenue forecast for Apollo Commercial Real Estate Finance Inc?
Projected CAGR
-50%
Over the last 14 years, the compound annual growth rate for Revenue has been 21%. The projected CAGR for the next 2 years is -50%.
What is the Operating Income forecast for Apollo Commercial Real Estate Finance Inc?
Projected CAGR
6%
Over the last 14 years, the compound annual growth rate for Operating Income has been 10%. The projected CAGR for the next 2 years is 6%.
What is the Net Income forecast for Apollo Commercial Real Estate Finance Inc?
Projected CAGR
18%
Over the last 14 years, the compound annual growth rate for Net Income has been 11%. The projected CAGR for the next 2 years is 18%.
